6. Zhu L, Xue H, Sun Z, et al. Prospective comparison of biphasic contrast-enhanced CT, volume perfusion CT, and 3 Tesla MRI with diffusion-weighted imaging for insulinoma detection. *J Magn Reson Imaging.* 2017;46:1648–1655.
7. Antwi K, Fani M, Heye T, et al. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. *Eur J Nucl Med Mol Imaging.* 2018;45:2318–2327.
8. Prasad V, Sainz-Esteban A, Arsenic R, et al. Role of ^{68}Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study. *Eur J Nucl Med Mol Imaging.* 2016;43:1593–1600.
9. Mehrabi A, Fischer L, Hafezi M, et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. *Pancreas.* 2014;43:675–686.
10. Brom M, Joosten L, Oyen WJ, Gotthardt M, Boerman OC. Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas. *Contrast Media Mol Imaging.* 2012;7:160–166.
11. Christ E, Wild D, Ederer S, et al. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. *Lancet Diabetes Endocrinol.* 2013;1:115–122.
12. Luo Y, Pan Q, Yao S, et al. Glucagon-like peptide-1 receptor PET/CT with ^{68}Ga-NOTA-exendin-4 for detecting localized insulinoma: a prospective cohort study. *J Nucl Med.* 2016;57:715–720.
13. Laje P, States LJ, Zhuang H, et al. Accuracy of PET/CT scan in the diagnosis of the focal form of congenital hyperinsulinism. *J Pediatr Surg.* 2013;48:388–393.
14. Fendrich V, Bartsch DK, Langer P, Zielke A, Rothmund M. Diagnosis and surgical treatment of insulinoma: experiences in 40 cases [in German]. *Dtsch Med Wochenschr.* 2004;129:941–946.
15. Kisker O, Bastian D, Frank M, Rothmund M. Diagnostic localization of insulinoma: experiences with 25 patients with solitary tumors [in German]. *Med Klin.* 1996;91:349–354.
16. Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. *J Clin Endocrinol Metab.* 2009;94:4398–4405.
17. DeLong JC, Hoffman RM, Bouvet M. Current status and future perspectives of fluorescence-guided surgery for cancer. *Expert Rev Anticancer Ther.* 2016;16:71–81.
18. Ash C, Dubec M, Donne K, Bashford T. Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods. *Lasers Med Sci.* 2017;32:1909–1918.
19. van Eyll B, Lankat-Buttgereit B, Bode HP, Goke R, Goke B. Signal transduction of the GLP-1-receptor cloned from a human insulinoma. *FEBS Lett.* 1994;348:7–13.
20. Jodal A, Lankat-Buttgereit B, Brom M, Schibli R, Behe M. A comparison of three $^{67/68}$Ga-labelled exendin-4 derivatives for beta-cell imaging on the GLP-1 receptor: the influence of the conjugation site of NODAGA as chelator. *EJNMMI Res.* 2014;4:31.
21. Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC. ^{68}Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. *Eur J Nucl Med Mol Imaging.* 2010;37:1345–1355.
22. Brom M, Woliner-van der Weg W, Joosten L, et al. Non-invasive quantification of the beta cell mass by SPECT with ^{111}In-labelled exendin. *Diabetologia.* 2014; 57:950–959.
23. Winer JH, Choi HS, Gibbs-Strauss SL, Ashitate Y, Colson YL, Frangioni JV. Intraoperative localization of insulinoma and normal pancreas using invisible near-infrared fluorescent light. *Ann Surg Oncol.* 2010;17:1094–1100.
24. Reiner T, Kohler RH, Liew CW, et al. Near-infrared fluorescent probe for imaging of pancreatic beta cells. *Bioconjug Chem.* 2010;21:1362–1368.
25. Reiner T, Thurber G, Gaglia J, et al. Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog. *Proc Natl Acad Sci USA.* 2011;108:12815–12820.
26. Brand C, Abdel-Atti D, Zhang Y, et al. In vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agent. *Bioconjug Chem.* 2014;25:1323–1330.
27. Eriksson O, Rosenstrom U, Selvaraju RK, Eriksson B, Velikyan I. Species differences in pancreatic binding of DO3A-VS-Cys^{40}-Exendin4. *Acta Diabetol.* 2017;54:1039–1045.
28. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. *Eur J Nucl Med Mol Imaging.* 2003;30:781–793.
29. Harlaar NJ, Koller M, de Jongh SJ, et al. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study. *Lancet Gastroenterol Hepatol.* 2016;1:283–290.
30. Lamberts LE, Koch M, de Jong JS, et al. Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study. *Clin Cancer Res.* 2017;23:2730–2741.
31. Miller SE, Tummers WS, Teraphongphom N, et al. First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800. *J Neurooncol.* 2018;139:135–143.
32. Joshi BP, Wang TD. Targeted optical imaging agents in cancer: focus on clinical applications. *Contrast Media Mol Imaging.* 2018;2018:2015237.

Erratum

In the article "Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study," by Hye Yoo et al. (*J Nucl Med.* 2020;61:33–39), an additional affiliation was inadvertently omitted for authors Seo Young Kang and Gi Jeong Cheon. The corrected author byline for Seo Young Kang and Gi Jeong Cheon should read: Seo Young Kang[2,5], Gi Jeong Cheon[2,5]. The added affiliation is [5]*Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea.* The authors regret the error.